Newsletter Subject

Early Signs of Parkinson's May Be Seen Years Before Diagnosis

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Sat, Nov 12, 2022 12:22 PM

Email Preheader Text

Weekly Review Saturday, November 12, 2022 WORDOSIS CME SPOTLIGHT ADVERTISEMENT CME SPOTLIGHT CME SPO

[MEDPAGE TODAY]( Weekly Review Saturday, November 12, 2022 [Early Signs of Parkinson's May Be Seen Years Before Diagnosis]( [Chronic Pain: Opioids No Longer Treatment of Choice]( [Leana Wen Skips APHA Talk Following Threats Against Her]( WORDOSIS [Play Today's Wordosis: Our Medical Word Game]( CME SPOTLIGHT [State-of-the-Art Care for Myelodysplastic Syndromes and Myeloproliferative Neoplasms]( [FDA Authorizes IL-1 Drug for Hospitalized COVID Patients]( [Don't Report Your Abortion Patients to Law Enforcement]( ADVERTISEMENT [Nurse Amputated Foot for Taxidermy Shop? Guilty Plea in Doctor's Forklift Death]( CME SPOTLIGHT [Advanced Bladder Cancer: Expert Insights on Navigating an Evolving Treatment Landscape]( [Study Refutes Heart Health Claims of Dietary Supplements]( [Alzheimer's Risk and COVID; Obesity in New MS Patients; Repurposing Telmisartan?]( [A Fork in the Road on My 'Cancer Journey']( CME SPOTLIGHT [Uncovering New Evidence in Higher-Risk Myelodysplastic Syndromes]( [Bariatric Surgery Cuts All-Cause Mortality Rate Over Many Years]( [Respiratory Virus Surge Chokes Up Health Systems, Not Just Children's EDs]( [Psilocybin for Depression; What's the Best Direct Oral Anticoagulant?]( CME SPOTLIGHT [COVID-19 Prevention for Immunocompromised Individuals: Ask the Experts]( [Internal Strife at America's Frontline Doctors: Simone Gold Accused of Misusing $$$]( [FDA Panel Backs Novel Combination Inhaler for Asthma in Adults Only]( [Eating Disorder Spike; $1M Fraud at Psych Clinic? Risperidone LAI Heads Back to FDA]( CME SPOTLIGHT [Genitourinary Cancers: Assessing the Roles of Immune-Based and Targeted Therapies in a Changing Treatment Landscape]( [Are Some Bipolar I Disorder Patients Mistakenly Getting an MDD Diagnosis?]( [Strong Showing for Novel BP-Lowering Drugs in Resistant Hypertension]( [Decision-Support Tool Enhances Outcomes for Heart Failure Patients in the ED]( CME SPOTLIGHT [Navigating New Evidence in the Treatment of Metastatic/Recurrent Cervical Cancer]( [Florida Medical Boards Ban Gender-Affirming Care for Kids]( [Anticoagulation Again Flops for Outpatient COVID-19]( [Lucky to Be Scoped]( CME SPOTLIGHT [The Many Faces of Head and Neck Cancer: Evolving Aspects of Multidisciplinary Care]( [Daily Protein Bars: A Filling Snack of Empty Calories?]( [Doctor Dives Into Online Therapy]( [300,000 Health Workers Left Medicine; Americans Avoiding Care Due to Insurance Fears]( CME SPOTLIGHT [Advancing Post-Transplant CMV Care: Prophylactic and Preemptive Management]( [Sjogren's Responds to Cytokine Treatment, Early Data Show]( [One in Five May Recall Near-Death Experience After CPR]( [The Little Suicide Construct That Could]( [Want a Few Weeks of Knee Pain Relief? Try This]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2022 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_DHE_Weekly?xid=nl_mpt_DHE_2022-11-12&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 345 Hudson Street 16th Floor New York, NY 10014

Marketing emails from medpagetoday.com

View More
Sent On

08/12/2024

Sent On

08/11/2024

Sent On

07/11/2024

Sent On

07/11/2024

Sent On

06/11/2024

Sent On

04/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.